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ABSTRACT
Purpose. The purpose of the present study was to analyze
clinicopathologic features and long-term prognosis of
gastric stump cancer (GSC) arising in the remnant stomach
5 years or later after partial gastrectomy for benign disease.
Methods. We reviewed the results of 176 patients resected
with curative intent for GSC at 8 Italian centers belonging
to the Italian Research Group for Gastric Cancer (GIRCG).
The median (range) follow-up time for surviving patients
was 71.2 (6–207) months.
Results. One hundred forty-six patients were men, the
mean age at the time of diagnosis was 69.2 years, and the
great majority (167 cases) underwent Billroth II recon-
struction. R0 resection was achieved in 158 (90 %)
patients, and in 94 (53 %) lymph node dissection was CD2.
Postoperative mortality and complication rates were 6.2
and 43.2 %, respectively. T1 tumor was diagnosed in 45
(25 %) cases. Lymph node metastases were evident in 86
patients (49 %). Thirteen patients had involvement of the
jejunal mesentery nodes (pJN?); five cases were T2–T3
and eight cases were T4. Overall 5-year survival rate was
53.1 %. Five-year survival rates were 68.1, 37.8, and
33.1 % for pT1, pT2-3, and pT4 tumors, respectively
(P = 0.001). Five-year survival rate was 56.5 % for node-
negative tumors (pN0), 32.3 % for tumors with nodal
metastases without involvement of jejunal mesentery nodes
(pN?), and 17.1 % for tumors with involvement of jejunal
mesentery nodes (pJN?) (P = 0.002).
Conclusions. Our study suggests that an aggressive sur-
gical approach can achieve a satisfactory outcome in GSC.
Patients with prior resection of the distal stomach for
peptic ulcer are at increased risk of developing gastric
stump cancer (GSC). This tumor is characteristically con-
sidered as a distinct clinical entity, and it is defined as a
gastric cancer that arises in the remnant stomach more than
5 years after primary surgery for benign disease.1–3 In
Western centers, its incidence ranges between 2.4 and 6 %
of all gastric cancer patients.3–7
Early diagnosis of GSC might be difficult, because most
patients are asymptomatic.8 GSC is usually described as a
tumor with poor prognosis and low resectability rates in the
range of 38–40 % because of extended lymph node
metastases and infiltration of adjacent organs. The reported
5-year survival rates ranges from 7 to 25 %, even after
curative resection.9 In the present study, we reviewed
clinicopathologic features and surgical outcome of GSC in
an Italian multicenter cohort.
PATIENTS AND METHODS
Definition
GSC was defined as a gastric cancer occurring in the
remnant stomach 5 years or later distal gastric resection for
benign disease.2,4 Tumors diagnosed as recurrence after distal
gastric resection for malignant disease or metachronous gas-
tric adenocarcinoma were excluded from the analysis.
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GSC was classified as: (a) anastomotic when the bulk of
the tumor involved the anastomotic site; (b) extra-anasto-
motic when the tumor was located outside the anastomotic
site; and (c) diffuse when the tumor involved the entire
gastric remnant. Patients affected by cancer involving the
esophagogastric junction were not included in the study.
Study Population
This study analyzed 176 patients resected with curative
intent for GSC from January 1990 and December 2012 in
eight Italian centers (Department of Surgery of the Uni-
versity of Verona, Department Surgery of the University of
Brescia, Department of Surgery of the Catholic University
of Rome, Department of Surgery of Forlı`, Department of
Surgery of the University of Siena, Second Clinical Sur-
gery of the University of Padua, Division of Surgical
Oncology of the Humanitas Hospital of Milan, Division of
Surgery of the Rovereto Hospital) belonging to the Italian
Research Group for Gastric Cancer (GIRCG).
No patient in the cohort underwent preoperative che-
motherapy and/or radiotherapy, or received adjuvant
chemotherapy. The study was approved by the local ethics
committees.
Extent of Resection and Lymphadenectomy
The main goal of surgery was to achieve a potentially
curative (R0) resection. Complete resection of the gastric
remnant with jejunal mesentery nodes was performed in any
case. The extent of lymph node dissection as well as the need
for splenectomy or other adjacent organ resection was estab-
lished by the operating surgeon in order to achieve a complete
resection. Postoperative complicationswere graded according
to the modified Clavien–Dindo classification system.10
Particularly, lymphadenectomy and lymph node retrie-
val were classified and standardized in accordance with the
second English edition of the Japanese Gastric Cancer
Association (JGCA) guidelines: dissection of group 1
nodes (D1); dissection of group 1 and 2 nodes (D2); dis-
section of group 1, 2, and 3 nodes (D3). Although lymph
node stations were not collected separately in all cases, the
incidence of metastasis for each single station was calcu-
lated as the percentage of patients with positive nodes in
that station among patients with separate dissection of that
station and with reference to the depth of invasion.11
STAGING AND HISTOLOGICAL
CLASSIFICATION
Tumors were staged according to the pathological clas-
sification (pTNM) of the 7th Edition of the International
Union Against Cancer (UICC).12 Lymph node involvement
was classified according to the number (UICC) 12 and site
(JGCA) of nodal metastasis.11 The histological classification
followed the criteria of Lauren.13
Follow-up and Survival Analysis
A total of 152 of the 176 patients were regularly fol-
lowed-up with a standardized protocol.14 Median follow-up
time for surviving patients was 71.2 (range 6–207) months.
Survival curves were estimated using the Kaplan–Meier
method and compared by the log-rank test. The time of sur-
vival measured was obtained starting from the date of surgery
to the date of death. Multivariable analysis was performed by
Cox regression model by taking into account the following
risk factors: age (higher thanmedianvs.medianor below), sex
(male vs. female), tumor location (extra-anastomotic and
diffuse vs. anastomotic), Lauren histotype (nonintestinal vs.
intestinal), R category (R1–2 vs. R0), M category (M1 vs.
M0), T category (pT2–T3 and pT4 vs. pT1), type of lym-
phadenectomy (D2–3 vs. D1), and extent of lymph node
involvement considered according to TNM classification
(pN1, pN2, pN3a and pN3b vs. pN0), as well as site of nodal
involvement (patients with nodal metastasis but negative
jejunal mesentery nodes and patients with nodal metastasis in
jejunal mesentery nodes vs. node negative patients). Causes
other than gastric cancerwere included in the survival analysis
(overall survival). Analyses were performed using the Sta-
tistical Package for the Social Sciences, SPSS 16.0 for
Windows, XP (SPSS, Chicago, IL, USA).
RESULTS
Principal Clinicopathological Characteristics
The main clinicopathological findings of the 176
patients under study are reported in Table 1.
One hundred forty-six patients were men (83 %). The
median and mean age at the time of diagnosis was 70 and
69.2 (range 42–87) years, respectively. The mean interval
between primary distal gastric resection and the develop-
ment of GSC was 34.6 (range 8–57) years. The great
majority of patients (167 cases) underwent Billroth II
reconstruction and 10 patients Billroth I.
Extent of Resection and Short-term Results
Resection of one or more adjacent organs often was
performed together with gastrectomy (70 patients). Sple-
nectomy (37 cases) and resection of the transverse colon (9
cases) were the procedures most frequently associated.
Extended (CD2) lymph node dissection was performed in
94 (53 %) patients. Complete tumor (R0) resection was
achieved in 90 % of the cases.
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Seventy-six patients (43.2 %) developed postoperative
general and/or surgical-related complications. Eleven
patients died (postoperative mortality 6.2 %). Pulmonary
complications (11.9 %), anastomotic leaks (10.2 %), and
cardiovascular complications (4.5 %) were the most fre-
quently observed complaints (Table 2). According to the
modified Clavien–Dindo classification system, complica-
tion rates for grades I, II, IIIa, IIIb, IVa, IVb, and V were
5.7 % (10/176), 15.3 % (27/176), 5.1 % (9/176), 4.5 % (8/
176), 2.8 % (5/176), 3.4 % (6/176), and 6.2 % (11/176),
respectively.
Histopathological Staging and Lymph Node
Involvement
In our study, one of four tumors was diagnosed as an
early gastric cancer, and one of two were without lymph
node metastasis. Moreover, 12 (7 %) patients were diag-
nosed with metastatic disease at the time of surgery: 9
patients suffered from hepatic metastasis and 3 from peri-
toneal metastasis. Tumor location was anastomotic in 71
(40 %) cases, extra-anastomotic in 73 (42 %) cases, and
diffuse in 32 (18 %) cases.
A total number of 3,376 lymph nodes were dissected
with a mean (SD) number per case of 19.2 (5.8) and a
median number of 16 (range 5–66). Lymph node metas-
tases were found in 86 patients (49 %), with a total of 664
metastatic lymph nodes. The mean (SD) and median
number of metastatic lymph nodes for node-positive
patients were 7.7 (7) and 5 (range 1–45), respectively.
Table 3a, b show lymph node involvement according to
depth of tumor invasion. Among the 13 patients with involve-
ment of jejunal mesentery nodes (pJN?), this was the only site
of nodal metastases in 4 cases of anastomotic tumors (31 %).
Survival
At the follow-up end date, 24 patients were lost at fol-
low-up procedure and therefore were excluded from
TABLE 1 Clinicopathological characteristics of the GSC patients
Characteristics Number of patients
Sex Male 146 (83)
Female 30 (17)
Mean age (years) 69.2; range 42–87
Primary operation Billroth I 10 (5)
Billroth II 167 (95)
Lymphadenectomy D1 82 (47)
CD2 94 (53)
Histotype Intestinal 104 (59)
Diffuse 44 (25)
Mixed 28 (16)
Tumor site Anastomotic 71 (40)
Extra-anastomotic 73 (42)
Diffuse 32 (18)
T category T1 45 (25)
T2–T3 56 (32)
T4a 42 (24)
T4b 33 (19)
N category N0 90 (51)
N1 21 (12)
N2 25 (14)
N3a 32 (18)
N3b 8 (5)
M category M0 164 (93)
M1 12 (7)
Type of resection Gastrectomy 106 (60)
Extended gastrectomy 70 (40)
Spleen 37 (21)
Colon 9 (5)
Liver 3 (2)
Pancreas 2 (1)
Others 3 (2)
Combined 16 (9)
Curability R0 158 (90)
R1 11 (6)
R2 7 (4)
Values in parentheses are in percentage
TABLE 2 Postoperative complications in the 176 patients studied
Type of complications Number of patients
Surgical-related
Anastomotic leak 18 (10.2)
Abdominal abscess 5 (2.8)
Abdominal hemorrhage 5 (2.8)
Pancreatic fistula 3 (1.7)
Anastomotic hemorrhage 2 (1.1)
Wound infection 2 (1.1)
Bowel infarction 2 (2.1)
Paralytic ileus 2 (2.1)
Biliary fistula 1 (0.6)
Severe pancreatitis 1 (0.6)
Lymphorrhea 1 (0.6)
Others 5 (2.8)
General
Pulmonary 21 (11.9)
Cardiovascular 8 (4.5)
Multiple
One or more of the previous 12 (6.8)
Total 76 (43.2)
Values in parentheses are in percentage
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survival analysis, 91 patients died, and 61 patients were
alive. The overall 2-, 3-, and 5-year survival rates for the
152 patients were 67.1, 55.9, and 53.1 %, respectively.
Median (95 % confidence interval [CI]) survival time was
42.5 (range 13.4–71.6) months after R0 resection and 9.7
(range 0–21.1) months when residual (R1–2) tumor was
present (P = 0.001). Figure 1 shows survival curves
according to the depth of tumor invasion. Five-year sur-
vival rates were 68.1, 37.8, and 33.1 % for pT1, pT2–3,
and pT4 tumors, respectively (P = 0.001). Figure 2 reports
survival curves according to nodal involvement. Five-year
survival rate was 56.5 % for node-negative tumors (pN0),
32.3 % for tumors with nodal metastases without
involvement of jejunal mesentery nodes (pN?) and 17.1 %
for tumors with involvement of jejunal mesentery nodes
(pJN?) (P = 0.002).
Multivariable analysis performed by Cox regression
model controlling for sex, age, tumor location, Lauren
histotype, curability, M category, T category, and extent of
lymphadenectomy-confirmed N category, classified
according to the 7th UICC Classification, to be an inde-
pendent predictor of survival (P = 0.011). When positive-
node patients were considered according to involvement of
mesentery jejunal nodes, no statistical significance was
observed [RR for pN? with respect to pN0: 1.33 (95 % CI
0.78–2.26); RR for pJN? with respect to pN0: 1.94 (95 %
CI 0.88–4.26); P = 0.239].
DISCUSSION
Several investigations have been conducted to evaluate
clinicopathological characteristics of patients with GSC,
but most of them involved patients with previous gastric
resection for cancer.
Although cancer can develop in the remnant stomach of
patients with previous benign or malignant lesions, these
tumors seem to be two different entities. Namely, the
patients with previous cancer develop stump carcinoma in
a significantly shorter time interval than those with prior
benign disease.15,16 Indeed, the most important factor
presumed to be responsible for the development of GSC is
duodenogastric reflux, whereas cancer after gastric resec-
tions for malignancy probably originates from the same
precancerous conditions which had already existed before
the initial operation.15,17,18 Moreover, the discrepancies in
the extent of gastric resection for benign or malignant
TABLE 3 Lymph node involvement according to depth of tumor invasion
(a) Incidence (%) of lymph node metastasis according to the UICC classification12
Depth of invasion N stage
N0 N1 N2 N3a N3b N?
T1a–T1b 43/45 1/45 1/45 0/45 0/45 2/45
(95.6) (2.2) (2.2) (0) (0) (4.4)
T2–T3 27/56 11/56 5/56 9/56 4/56 29/56
(48.2) (19.6) (8.9) (16.1) (7.1) (51.8)
T4a–T4b 20/75 9/75 19/75 23/75 4/75 55/75
(26.7) (12) (25.3) (30.7) (5.3) (73.3)
Total 90/176 21/176 25/176 32/176 8/176 86/176
(51.1) (11.9) (14.2) (18.2) (4.5) (48.9)
(b) Incidence (%) of metastasis in the JGCA lymphatic stations 11
Depth of invasion Lymphatic station
No. 1 No. 2 No. 3 No. 4sa No. 4sb No. 7 No. 8 No. 9 No. 10 No. 11 No. Ja
T1a–T1b 0/24 0/22 1/23 0/21 0/22 1/13 0/15 0/8 0/9 0/7 0/6
(0) (0) (4.3) (0) (0) (7.7) (0) (0) (0) (0) (0)
T2–T3 4/19 3/17 3/18 0/16 1/18 3/9 1/12 2/10 0/8 0/10 5/9
(21) (17.6) (16.7) (0) (5.5) (33.3) (8.3) (20) (0) (0) (55.5)
T4a–T4b 6/38 5/39 17/42 3/34 7/35 6/29 3/21 3/11 3/13 2/11 8/13
(15.8) (12.8) (40.5) (8.8) (20) (20.7) (14.3) (27.3) (23.1) (18.2) (61.5)
Total 10/81 8/78 21/83 3/71 8/75 10/51 4/48 5/29 3/30 2/28 13/28
(12.3) (10.3) (25.3) (4.2) (10.7) (19.6) (8.3) (17.2) (10) (7.1) (46.4)
a Jejunal lymph nodes
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disease and lymph node dissection, which is performed
only in case of cancer, will lead to different pathways of
local invasion and lymphatic spread.15,18,19
This Italian multicenter study only deals with GSC
arising after gastric resection for benign disease. GSC
remains a substantial clinical concern.6 Indeed, gastric
resection for benign disease was commonly performed
until the late 1980s, and it is still less frequently conducted
in case of emergent and life-threatening complications of
peptic ulcer disease, such as bleeding and perforation,
refractory ulcer disease, and recurrent ulcer with gastric
outlet obstruction.20–22 Because patients develop the tumor
after a long latency period, which can be more than
30 years (as in our cases), GSC will continue to be
encountered by surgeons.4–7,23–25
Several authors have reported a higher risk of develop-
ing GSC in men and after Billroth II reconstruction. In the
present series, the great majority (83 %) of patients
affected by GSC were men, and 167 (95 %) underwent
Billroth II reconstruction. The male predominance could be
explained with the higher incidence of peptic disease in
men.8 With regards to the type of surgical reconstruction, it
has been found a fourfold increased risk of developing
gastric carcinoma as a consequence of Billroth II procedure
in comparison to Billroth I,26 but it should be considered
that in Italy, until 1980, Billroth I was less popular in
surgical treatment of peptic disease.3,8,25,27–29
Despite the relatively high rate of cases with early
cancer (25 %), and with no lymph node metastasis (51 %),
surgeon performed extended (D2) or superextended (D3)
lymphadenectomy in 94 patients (53 %), and gastrectomy
with combined resection of one of more adjacent organs in
70 (40 %). We registered a relatively higher frequency of
D1 (47 %) than that reported in previous studies (22-
32 %),3,19,30,31 because this multicenter study included
patients operated on between January 1990 and December
2012. Indeed, especially during the first period of study, the
superiority of D2 lymphadenectomy was not demonstrated,
hence some of the centers were less prone to adopt
extensive lymphadenectomy. Another reason for this pro-
portion of D1 lymphadenectomies is that a huge number of
patients were at an advanced age at the moment of surgery.
This is demonstrated by the median age of the cohort
(70 years) and by the percentage of patients C75 years
(approximately 30 %). Indeed, multivariable analysis
demonstrated a superiority of D2–D3 versus D1 lym-
phadenectomy [RR for D2–3 with respect to D1: 1.65
(95 % CI 1.03–2.63); P = 0.036], but we believe that such
a debated issue was beyond the purpose of a study with this
sample size.
We registered a high rate (90 %) of curative resection
(R0), which was similar to the rates of 85 and 91 %
reported in two recent studies, where the surgical man-
agement was based on an aggressive surgical approach.4,7
This therapeutic strategy, recommended by several authors,
includes complete removal of the whole remnant stomach
with resection of adjacent organs in requiring cases, toge-
ther with an extended lymphadenectomy.5–7,32
In the present series, the postoperative morbidity
(43.2 %) and mortality (6.2 %) resulted in higher than
previous reports of GIRCG in gastric cancer surgery.33
FIG. 1 Kaplan–Meier estimates of overall survival probability of the
cohort under study who completed the follow-up procedure (152
patients) according to depth of tumor invasion. Median (95 CI)
survival times were: beyond the observation period for pT1 tumors,
30 (range 13.3–46.8) months for pT2 tumors and 24.3 (range 15.5–
33.2) months for pT3–T4 tumors (P = 0.001)
FIG. 2 Kaplan–Meier estimates of overall survival probability of the
cohort under study who completed the follow-up procedure (152
patients) according to level of nodal involvement. Median (95 CI)
survival times were: 88.2 (range 6.7–169.7) months for node-negative
tumors (pN0), 29.3 (19.8–38.9) months for node-positive tumors
(pN?), and 23.5 (range 0–47.9) months for pN? tumors with
involvement of jejunal mesentery nodes (pJN?) (P = 0.002)
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These results can be attributed to the major effort a surgeon
should manage to treat this tumor compared with conven-
tional gastric cancer: for instance, the low incidence of
GSC, the presence of adhesion between the gastric stump
and other organs due to the initial surgery, and the common
removal of adjacent organs.2,31,32 Moreover, morbidity and
mortality observed in this series is probably related to
median patient age (70 years) and to associated organ
resection, which was quite frequent (70 cases).
Previous studies conducted on early gastric stump can-
cer reported a low incidence of nodal involvement, which
is less than 6 %.34–36 We found 45 patients (25 %) affected
by early cancer, of which only 2 (4.4 %) presented lymph
node metastases. These pathological findings support that
endoscopic mucosal resection (EMR) and endoscopic
submucosal dissection (ESD) can be useful for the treat-
ment of selected cases of early gastric stump cancer.36,37
Some authors have investigated the pattern of lymphatic
spread of GSC in comparison with the upper third primary
gastric cancer. Their results suggested that these two types
of gastric tumors have a different lymphatic spread,3,22,36
and our results seems to confirm this findings. As we
reported in a previous study, the main lymphatic flow
drains from a tumor located in the upper third of the
stomach into nodes along the lesser curvature, the right
cardia, the left gastric artery, and the celiac artery.38 In
GSC, these lymphatic pathways have been cut off; indeed,
previous partial gastrectomy, usually causes lymphatic
leakage, blockage, and regeneration of lymphatic flow
around the gastric stump and also induces abnormal lym-
phatic formation.32,36 Moreover, as recently reported by Li
et al.39 because of initial distal gastrectomy, the total
number of lymph nodes and the amount of metastatic
lymph nodes are lower in GSC than in conventional gastric
cancer.
Four patients with anastomotic GSC had jejunal mes-
entery nodes involvement without simultaneous invasion of
any other lymph node station. This observation is in
agreement with the rules of the Japanese classifications of
gastric carcinoma that identified jejunal mesentery nodes as
group 1–group 2 if the tumor invades the jejunum, and as
group 2–group 3 if there is no jejunal invasion.11
Although in our experience, overall 5-year survival rate
reached 50 % and seems to be better than in recent Western
series,4,6 it is consistent with previous studies.3,5,24,31,36
This result might be related to the relatively high rate of
early stage disease (25 %), as 5-year survival rate was
approximately 35 % for patients with advanced forms.
Early tumors showed the best prognosis (5-year survival
rate was 68.1 %), although it was poorer compared to
primary early gastric cancer. This outcome reflects the
advanced age of the cohort under study, in which cardio-
vascular diseases were the leading causes of death (70 %).
The reported prognosis of patients with infiltrated lymph
nodes in the jejunal mesentery is poor; Thorban et al.4
reported a median survival of 13.2 months. In the present
series, patients with metastases in jejunal mesentery nodes
(pJN?) had the worst outcome (5-year survival rate was
17.1 % and median survival time was 23.5 months),
although the difference with node-positive patients did not
reach statistical significance.
In conclusion, the results of this study suggest that early
diagnosis allows the best surgical outcome in patients with
GSC. An aggressive surgical approach can achieve a sat-
isfactory outcome in advanced stages.
DISCLOSURE All the authors declare that they have not potential
commercial conflicts of interest relevant to this article.
REFERENCES
1. Balfour DC. Factors influencing the life expectancy of patients
operated on for gastric ulcer. Ann Surg. 1922;76:405–8.
2. Safatle-Ribeiro AV, Ribeiro U Jr, Reynolds JC. Gastric stump
cancer: what is the risk? Dig Dis. 1998;16:159–68.
3. Barillari P, Aurello P, Manetti G, Broglia S, Cioe` I, Piovanello P,
Naticchioni E. Carcinoma of the gastric stump. Our experience in
28 treated cases. Minerva Chir. 1997;52:713-6.
4. Thorban S, Bo¨ttcher K, Etter M, Roder JD, Bush R, Siewert JR.
Prognostic factors in gastric stump cancer. Ann Surg.
2000;231:188–94.
5. Schaefer N, Sinning C, Standop J, Overhaus M, Hirner A, Wolff
M. Treatment and prognosis of gastric stump carcinoma in
comparison with primary proximal gastric cancer. Am J Surg.
2007;194:63–7.
6. Firat O, Guler A, Sozbilen M, Ersin S, Kaplan H. Gastric remnant
cancer: an old problem with novel concerns. Langenbecks Arch
Surg. 2009;394:93–7.
7. Mezhir JJ, Gonen M, Ammori JB, Strong VE, Brennan MF, Coit
DG. Treatment and outcome of patients with gastric remnant
cancer after resection for peptic ulcer disease. Ann Surg Oncol.
2011;18:670–6.
8. Gandolfi L, Vaira D, Bertoni F, Rossi A, Solmi L, Leo P, Mu-
ratori R. Cancer of gastric stump in Italy, 1979-1986.
Gastrointest Endosc. 1988;34:242–6.
9. Sinning C, Schaefer N, Standop J, Hirner A, Wolff M. Gastric
stump carcinoma—epidemiology and current concepts in patho-
genesis and treatment. Eur J Surg Oncol. 2007;33:133–9.
10. Dindo D, Demartines N, Clavien PA. Classification of surgical
complications. A new proposal with evaluation in a cohort of
6336 patients and results of a survey. Ann Surg. 2004;240:205–
13.
11. Japanese Gastric Cancer Association. Japanese classification of
gastric carcinoma, 2nd English edition. Gastric Cancer.
1998;1:10–24.
12. Sobin LH, Wittekind C, Gospodarowicz M, eds. TNM classifi-
cation of malignant tumors (UICC), 7th edn. New York: Wiley-
Blackwell; 2009:73–7.
13. Lauren P. The two histological main types of gastric carcinoma:
diffuse and so-called intestinal-type carcinoma. An attempt at a
histo-clinical classification. Acta Pathol Microbiol Scand.
1965;64:31–49.
14. Marrelli D, De Stefano A, de Manzoni G, Morgagni P, Di Leo A,
Roviello F. Italian research group for gastric cancer. Prediction of
recurrence after radical surgery for gastric cancer: a scoring
Clinicopathological Features and Outcomes of GSC 2599
system obtained from a prospective multicenter study. Ann Surg.
2005;241:247–55.
15. Furukawa H, Iwanaga T, Hiratsuka M, et al. Gastric remnant
cancer as a metachronous multiple lesion. Br J Surg. 1993;80:50–6.
16. Tanigawa N, Nomura E, Lee SW, et al. Current state of gastric
stump carcinoma in Japan: based on the results of a nationwide
survey. World J Surg. 2010;34:1540–7.
17. Sitarz R, Maciejewski R, Polkowski WP, Offerhaus GJA. Gast-
roenterostoma after Billroth antrectomy as a premalignant
condition. World J Gastroenterol. 2012;18:3201–6.
18. Kondo K. Duodenogastric reflux and gastric stump carcinoma.
Gastric Cancer. 2002;5:16–22.
19. Tanigawa N, Nomura E, Niki M, et al. Clinical study to identify
specific characteristics of cancer newly developed in the remnant
stomach. Gastric Cancer. 2002;5:23–8.
20. Guzzo JL, Duncan M, Bass BL, Bass BL, Bochicchio GV,
Napolitano LM. Severe and refractory peptic ulcer disease: the
diagnostic dilemma: case report and comprehensive review. Dig
Dis Sci. 2005;50:1999-2008.
21. Kuwabara K, Matsuda S, Fushimi K, Ishikawa KB, Horiguchi H,
Fujimori K. Reappraising the surgical approach on the perforated
gastroduodenal ulcer: should gastric resection be abandoned? J
Clin Med Res. 2011;213–22.
22. Czymec R, Großmann A, Roblick U, Fischer F, Bruch HP, Hil-
debrand P. Surgical management of acute upper gastrointestinal
bleeding: still a major challenge. Hepatogastroenterology.
2012;59:768–73.
23. Pointner R, Shwab G, Ko¨nigsrainer A, Bodner E, Shmid KW.
Gastric stump cancer: etiopatological and clinical aspects.
Endoscopy. 1989;21:115–9.
24. Chen CN, Lee WJ, Lee PH, Chang KJ, Chen KM. Clinicopath-
ologic characteristics and prognosis of gastric stump cancer. J
Clin Gastroenterol. 1996;23:251-5.
25. La Vecchia C, Negri E, D’Avanzo B, Moller H, Franceschi S.
Partial gastrectomy and subsequent gastric cancer risk. J Epi-
demiol Community Health. 1992;46:12–4.
26. Lundega˚rdh G, Adami HO, Helmick C, Zack M, Meirik O.
Stomach cancer after partial gastrectomy for benign ulcer disease.
N Engl J Med. 1988;319:195–200.
27. Cunsolo A, Spangaro M, Principe A, et al. The Billroth II gas-
trectomy in surgical treatment of duodenal ulcer. Clinico-
statistical studies of 784 operated cases. Minerva Dietol Gas-
troenterol. 1980;26:13–26.
28. Petrin C, Del Gaudio A. Billroth II gastric resection (100
homogeneous cases). Chir Ital. 1983;35:398–401.
29. Vigoni A, Marcato M, Mandelli L, Corradini C. Long-term
evaluation of the treatment of peptic ulcer by the Billroth II
method. Chir Ital. 1986;38:555–9.
30. Newman E, Brennan MF, Hochwald SN, Harrison L, Karpeh MS.
Gastric remnant carcinoma: just another proximal gastric cancer
or a unique entity? Am J Surg. 1997;173:292–7.
31. Sasako M, Maruyama K, Kinoshita T, Okabayashi K. Surgical
treatment of carcinoma of the gastric stump. Br J Surg.
1991;78:822–4.
32. Verlato G, Roviello F, Marchet A, Giacopuzzi S, Marrelli D, Nitti
D, de Manzoni G. Indexes of surgical quality in gastric cancer
surgery: experience of an Italian network. Ann Surg Oncol.
2009;16:594–602.
33. Han SL, Hua YW, Wang CH, JI SQ, Zhuang J. Metastatic pattern
of lymph node and surgery for gastric stump cancer. J Surg
Oncol. 2003;82:241–6.
34. Pointer R, Schwab G, Ko¨nigsrainer A, Bodner E. Early cancer of
the gastric remnant. Gut. 1988;29:298–301.
35. Sowa M, Onoda N, Nakanishi I, Maeda K, Yoshikawa K, Kato Y,
Chung YS. Early stage carcinoma of the gastric remnant in Japan.
Anticancer Res. 1993;13:1835–8.
36. Imada T, Rino Y, Hatori S, et al. Clinicopathologic differences
between early gastric remnant cancer and early primary gastric
cancer in the upper third of the stomach. Hepatogastroenterol-
ogy. 2000;47:1186-8.
37. Nishide N, Ono H, Kakushima N, Takizawa K, Tanaka M,
Matsubayashi H, Yamaguchi Y. Cinical outcomes of endoscopic
submucosal dissection for early gastric cancer in remnant stom-
ach or gastric tube. Endoscopy. 2012;44:577–83.
38. Di Leo A, Marrelli D, Roviello F, et al. Lymph node involvement
in gastric cancer for different tumor sites and T stage. Italian
Research Group for Gastric Cancer (IRGGC) experience. J
Gastrointest Surg. 2007;11:1146–53.
39. Li F, Zhang R, Liang H, Liu H, Quan J, Zhao J. The pattern of
lymph node metastasis and the suitability of 7th UICC N stage in
predicting prognosis of remnant gastric cancer. J Cancer Res Clin
Oncol. 2012;138:111–7.
2600 A. Leo et al.
